Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
OraSure Technologies, Inc. files its Annual Report on Form 10-K describing its diagnostics and sample-management businesses, product portfolio, regulatory status, manufacturing footprint and certain 2025 developments.
The report states an aggregate market value of common equity held by non-affiliates of $218,472,693 and 69,126,173 shares outstanding as of February 28, 2026. It discloses the November 2025 acquisition of BioMedomics, 2025 product and pipeline highlights including FDA 510(k) submissions for a CT/NG rapid molecular self-test and a Colli-Pee at-home urine device, ongoing EUA and CLIA statuses for InteliSwab products, BARDA funding for Ebola test development, and continued U.S. manufacturing capacity including a target of more than 100 million tests annually.
OraSure Technologies, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on five key items, including electing three Class II directors and declassifying the Board over three years. Proposals also seek to ratify Grant Thornton LLP, approve executive pay, and amend the Stock Award Plan to add 5,000,000 shares and extend it ten years. The company highlights 2025 net revenue of $115 million, approximately $199 million in cash with no debt, about $19 million in annualized cost savings, and a $40 million repurchase program under which $15 million and 5.3 million shares were repurchased in 2025.
OraSure Technologies Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 3,484,438 shares of Common Stock, representing 5.04% of the class. The filing shows sole voting power for 453,550 shares and sole dispositive power for 3,484,438 shares, and explains holdings include securities held for Vanguard funds and certain affiliates.
OraSure Technologies is soliciting proxies for its virtual 2026 Annual Meeting on June 3, 2026. The Board asks shareholders to: elect three Class II directors; ratify Grant Thornton LLP as auditor; approve advisory executive compensation; approve a 5,000,000-share increase to the Stock Award Plan (raising available shares to 6,982,477); and approve declassification of the Board over three years. The record date for voting is April 10, 2026, when 71,965,612 shares were outstanding. The filing reviews 2025 performance: $115M net revenue, $199M cash, no debt, $15M of share repurchases executed (part of a $40M authorization), and $19M of annualized run-rate cost savings.
Altai Capital Management and related reporting persons beneficially own 3,613,836 shares of OraSure Technologies common stock, representing 5.2% of the class. They entered a Cooperation Agreement under which OraSure will appoint John Bertrand to the Board and support his election at the 2026 annual meeting.
The Board committed to seek stockholder approval in 2026 to declassify the Board, moving toward annual director elections. The agreement grants Altai quarterly access to management and the Board, includes voting commitments and standstill provisions, and restricts the group from acquiring more than 9.9% of outstanding shares. The Cooperation Agreement generally runs until March 31, 2027, unless terminated earlier under its terms.
OraSure Technologies entered into a Cooperation Agreement with Altai Capital, under which Altai withdraws its prior director nominations and stockholder proposal and agrees to certain voting and standstill terms through March 31, 2027. The Board appointed John D. Bertrand as an independent Class II director and to the Nominating and Corporate Governance Committee, with his term expiring at the 2026 annual meeting. OraSure will seek stockholder approval at the 2026 annual meeting to declassify the Board, phasing in annual elections for all directors. The company agreed not to increase Board size above eight directors before the 2027 annual meeting without Altai’s consent. Bertrand will receive an initial time-vested equity award of common stock valued at $100,000, vesting two years after grant.
Orasure Technologies Inc Schedule 13G filed reporting aggregate beneficial ownership figures for Neil Gagnon and entities he controls. The filing lists Neil Gagnon with 3,754,846 shares (5.4%), Gagnon Securities LLC with 1,929,799 shares (2.8%), and Gagnon Advisors, LLC with 1,207,440 shares (1.7%). The percent calculations are based on 69,126,173 shares outstanding as of February 28, 2026. The filing states that Gagnon and the advisory entities may be deemed to share voting and dispositive power over these accounts and that the advisers expressly disclaim beneficial ownership of securities held in client accounts.
OraSure Technologies director Steven Kyle Boyd reported routine equity compensation activity. He received a grant of 5,246 shares of common stock at $3.0975 per share value under the company’s Stock Award Plan, with immediate vesting and issued in lieu of cash director fees.
To cover taxes on the vesting, 1,416 shares were withheld, a non-market disposition used to pay the related tax liability. After these transactions, Boyd directly owns 38,462 shares of OraSure common stock. The filing reflects standard board compensation rather than open-market buying or selling.
OraSure Technologies furnished an investor presentation addressing its business performance, governance and engagement with Altai Capital ahead of the 2026 annual meeting. The company highlights a focused diagnostics strategy, expecting revenue growth, margin expansion and operating cash flow breakeven in the first half of 2026.
Management points to stabilizing public health funding, planned launches of the Colli-Pee urine collection device and Sherlock CT/NG self-test, and a strong balance sheet with $199 million cash and no debt. A $40 million share repurchase program began in 2025, with $15 million already deployed at an average price of $2.85. The presentation also shows 2025 non‑GAAP gross margin of 42.6% on revenue of $115,021, compared with 39.9% on $387,479 in 2022, and discusses non‑GAAP measures and extensive forward‑looking risks.
OraSure Technologies Inc: Amendment No. 10 to a Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.
The form lists Vanguard's address and notes the filing was signed by Ashley Grim, Head of Global Fund Administration on 03/27/2026. The filing classifies this holding as ownership of 5 percent or less.